Thermo Fisher Scientific (TMO), the world's largest life sciences tools and services provider, serves pharmaceutical, biotech, diagnostics, and research customers worldwide. Because its results span laboratory consumables, analytical instruments, clinical diagnostics, and contract pharma services, its quarterly report is closely watched as a read on global health-care and biopharma spending. The company has now beaten earnings estimates for four consecutive quarters, and investors use this report to gauge whether demand momentum from earlier in 2026 is continuing. The third quarter also tested how well recent acquisitions, including Clario, are integrating and whether margin expansion is sustainable beyond one-time items. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Thermo Fisher Scientific (TMO) delivered third quarter 2026 adjusted EPS of $6.68, exceeding the consensus estimate of $6.40. Revenue came in at $12.14 billion, ahead of the roughly $11.95 billion expected and up 9% year over year, including 6% organic growth. Adjusted operating income rose 15% to $2.97 billion, and the adjusted operating margin expanded 120 basis points to 24.5%, above the 24% analysts had modeled.
Results were mixed by segment. Laboratory Products and Biopharma Services generated $6.86 billion in revenue, up 15% and above forecasts. Analytical Instruments revenue rose 5.8% to $2.00 billion, while Life Sciences Solutions grew 5.1% to $2.72 billion, slightly below expectations. Specialty Diagnostics declined 6.5% to $1.10 billion, also below consensus.
Management also raised full-year 2026 guidance. Revenue is now expected in a range of $47.7 billion to $48.2 billion, representing 7% to 8% reported growth, while adjusted EPS guidance was lifted to $25.13 to $25.43, implying 10% to 11% growth over 2025. Notably, about $0.15 of the quarterly EPS beat stemmed from one-time tariff refunds recovered during the period, which management said was not included in prior guidance.
Heading into the report, life sciences tools and services stocks had traded relatively flat over the prior month, with investors awaiting confirmation that demand strength seen earlier in 2026 was persisting. The third quarter beat on both revenue and EPS, coupled with a second consecutive full-year guidance raise, was broadly viewed as a sign that end-market conditions remain constructive, particularly in bioproduction and pharma services. Investors also took note of the meaningful margin expansion, though some analysts flagged that the tariff refunds inflated the quarterly figure on a one-time basis. The softer results in Specialty Diagnostics tempered enthusiasm, reminding the market that not all segments are growing at the same pace.
Looking ahead, investors will focus on whether Thermo Fisher Scientific (TMO) can sustain organic growth and margin gains without the benefit of one-time items. Management pointed to continued strength in customer activity and improving end markets, but the roughly $0.15 per share of tariff-related benefit in the third quarter will not repeat, so fourth quarter comparisons will be watched closely.
Acquisition integration remains a key theme. The Clario acquisition, which strengthens Thermo Fisher's clinical development offering, is performing well, and management expects meaningful revenue synergies over time. The filtration and separation business, which recently marked its one-year anniversary, continues to bolster bioproduction capabilities. The company also completed the divestiture of its microbiology business during the quarter, a reminder that portfolio shaping remains part of its capital deployment strategy.
Other factors to monitor include foreign exchange effects, which provided a modest tailwind in the quarter, and the pace of margin expansion driven by the company's productivity programs and its growing use of AI. Demand signals from pharmaceutical and biotech customers, along with trends in diagnostic testing volumes, will also shape whether the raised full-year guidance proves conservative. Investors should watch for further commentary on capital deployment, including potential M&A and share repurchases.
I’ve found Tickeron’s AI Screener to be a practical addition to my routine when reviewing earnings like these. The tool lets me quickly filter life sciences names by fundamentals, growth trends, and technical signals, helping confirm how Thermo Fisher Scientific (TMO) stacks up against peers without spending hours on manual work. It’s become one of the first places I turn for context on sector momentum.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TMO declined for three days, in 198 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMO as a result. In 46 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 23 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
TMO moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
TMO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 155 of 256 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (67.298). P/E Ratio (37.333) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties